Supportan Range | Oncology ONS/Tube Feeds | HCP

The Supportan® Range

Supporting Oncology Patients at Risk of Malnutrition

A woman in a headscarf stands smiling behind her child thanks to the cancer-specific nutritional support provided by Fresubin's Supportan range. The Supportan range includes tube feeds as well as Supportan Drink in a range of flavours, including Chocolate and Cappuccino.

The Supportan® Range

Managing Nutritional Risk in Oncology

Malnutrition, sarcopenia and cachexia affect more than 50% of people living with cancer¹⁻³, with consequences including poorer overall survival⁴, reduced quality of life⁵, and longer hospital stays and post-operative complications.⁶˒⁷

Rich in Protein and Omega-3 From Fish Oil

Supportan* offers patients 20 g of protein per 200 ml bottle, as well as 1g eicosapentaenoic acid (EPA) from fish oil per 200 ml bottle.

Patient-centric formats

Available in oral or tube feeding formats designed around patients’ needs.

A Range of Flavours

Palatability is key to compliance, especially as cancer and its treatment can change patients’ tastes.

Managing Nutritional Risk in Oncology

Nutrition can support better outcomes for your oncology patients, but changing tastes and reduced appetites can make it hard for them to meet their needs.¹ Oral and enteral nutritional supplements can provide a way to close nutritional gaps, even when tolerance to food is impaired.⁹

Malnutrition is independently associated with poorer tolerance to treatment⁸, increased complications^6,7, and reduced quality of life.₅ Supportan is specifically designed for the dietary management of cancer patients in case of or at risk of malnutrition, especially chronic catabolic disease and/or cachexia.

Fresubin's Supportan Drink range for oncology patients is available in a range of flavours, including Pineapple-Coconut, Tropical Fruits, Cappuccino and Chocolate.

Support The Full Journey

Supportan* offers a way to support your patients through every step of their treatment journey, whether they’re pre- or post-surgery, undergoing treatment or in rehabilitation.

As well as delivering the nutritional content to support optimal nutritional and clinical outcomes, the range also offers a variety of flavours, aiding adherence even as tastes change.

A woman smiles as she speaks on the phone whilst lying on a bed next to a Fresubin tube feed that supports her nutritional needs and cancer treatment.

Specialist Oncology Formula Across Two Delivery Formats

Supportan uses a high-fat, low-carbohydrate macronutrient profile (40% / 31% energy), with high protein (27% energy) and omega-3 fatty acids from fish oil (1 g EPA per 200 ml bottle), aligned with ESPEN and ESMO guidelines for oncology nutrition.^9,10

Available as ONS (300 kcal, 20 g protein per 200 ml) and as a tube feed, providing the same specialised formula for patients where oral intake is insufficient.

Fresubin's Supportan Drink contains 20g protein per bottle, 1g EPA from fish oil per bottle and MCT as a rapidly absorbed energy source. The Supportan Drink is lactose-free and fibre-containing.

Fresubin® ONS

Discover our wide range of Oral Nutritional Supplements.

Fresubin® Tube Feeds

Explore Fresubin®'s Tube Feed Ranges.

Supportan factsheets can be downloaded here:

Supportan Drink Factsheet

Filename: Supportan_Drink_FS_HCP_Jul26.pdf
Size: 311 KB
Format: pdf

Supportan Factsheet

Filename: Supportan_FS_HCP_Jul26.pdf
Size: 1 MB
Format: pdf

*Supportan products are food for special medical purposes, to be used under medical supervision. For the dietary management of patients with or at risk of disease-related malnutrition, in particular with cancer, chronic catabolic diseases and/or cachexia.

References:

1) Caillet P, Liuu E, Raynaud Simon A, Bonnefoy M, Guerin O, Berrut G, Lesourd B, Jeandel C, Ferry M, Rolland Y, Paillaud E. Association between cachexia, chemotherapy and outcomes in older cancer patients: A systematic review. Clin Nutr. 2017 Dec;36(6):1473-1482. doi: 10.1016/j.clnu.2016.12.003. Epub 2016 Dec 18. PMID: 28017447.

2) von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):507-509. doi: 10.1002/jcsm.12167. Epub 2016 Nov 2. PMID: 27891294; PMCID: PMC5114624.

3) Hébuterne X, Lemarié E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014 Feb;38(2):196-204. doi: 10.1177/0148607113502674. PMID: 24748626.

4) Zhang X, Tang T, Pang L, Sharma SV, Li R, Nyitray AG, Edwards BJ. Malnutrition and overall survival in older adults with cancer: A systematic review and meta-analysis. J Geriatr Oncol. 2019 Nov;10(6):874-883. doi: 10.1016/j.jgo.2019.03.002. Epub 2019 Mar 24. PMID: 30917937.

5) de Oliveira LC, Abreu GT, Lima LC, Aredes MA, Wiegert EVM. Quality of life and its relation with nutritional status in patients with incurable cancer in palliative care. Support Care Cancer. 2020 Oct;28(10):4971-4978. doi: 10.1007/s00520-020-05339-7. Epub 2020 Feb 7. PMID: 32034514.

6) D'Almeida CA, Peres WAF, de Pinho NB, Martucci RB, Rodrigues VD, Ramalho A. Prevalence of Malnutrition in Older Hospitalised Cancer Patients: A Multicenter and Multiregional Study. J Nutr Health Aging. 2020;24(2):166-171. doi: 10.1007/s12603-020-1309-4. PMID: 32003406; PMCID: PMC12879073.

7) Na BG, Han SS, Cho YA, Wie GA, Kim JY, Lee JM, Lee SD, Kim SH, Park SJ. Nutritional Status of Patients with Cancer: A Prospective Cohort Study of 1,588 Hospitalised Patients. Nutr Cancer. 2018 Nov-Dec;70(8):1228-1236. doi: 10.1080/01635581.2019.1578392. Epub 2019 Mar 22. PMID: 30900926.

8) Daly LE, Power DG, O'Reilly Á, Donnellan P, Cushen SJ, O'Sullivan K, Twomey M, Woodlock DP, Redmond HP, Ryan AM. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer. 2017 Jan;116(3):310-317. doi: 10.1038/bjc.2016.431. Epub 2017 Jan 10. PMID: 28072766; PMCID: PMC5294486.

9) Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Hütterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Mühlebach S, Oldervoll L, Ravasco P, Solheim TS, Strasser F, de van der Schueren M, Preiser JC, Bischoff SC. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021 May;40(5):2898-2913. doi: 10.1016/j.clnu.2021.02.005. Epub 2021 Mar 15. PMID: 33946039.

10) Arends J, Strasser F, Gonella S, Solheim TS, Madeddu C, Ravasco P, Buonaccorso L, de van der Schueren MAE, Baldwin C, Chasen M, Ripamonti CI. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open. 2021 Jun;6(3):100092.